ImmuneBridge has just secured a seed round from investors to scale its proprietary cell therapy. The capital is earmarked for scaling cell therapy manufacturing and advancing both internal and partner-led clinical pipelines.

Cell therapy is facing a manufacturing crisis. While the cell therapy market is projected to grow from $7 billion in 2025 to $$55 billion by 2035, current production methods are facing a bottleneck. Existing donor based methods face high clinical variability and are difficult to scale. Using induced pluripotent stem cells scales well but often produce lower quality cells that require expensive genetic engineering to function effectively.

ImmuneBridge’s solution is to utilize hematopoietic stem cells (HSCs) derived from umbilical cord blood. Their core technology, IBR403, A proprietary small molecule that allows for a 100,000-fold proliferation of stem cells while maintaining their original quality. This technology can potentially produce tens of thousands of therapeutic doses from a single unit of cord blood, significantly outperforming current industry standards which only produce tens of doses.

ImmuneBridge is working with over a dozen collaborators to develop various cell types, including NK cells, T cells, macrophages, and neutrophils. This year, the company aims to provide animal efficacy data for the lead program and is targeting for initial human trials by 2028. The company aims to have ten different therapies in clinical stages within the next decade.